Aficamten (CK-3773274) PDUFA date: FDA decision expected November 14, 2026
The FDA is expected to decide on Aficamten (CK-3773274) from Cytokinetics, Incorporated in Obstructive hypertrophic cardiomyopathy (label update based on MAPLE-HCM) by the PDUFA target action date of November 14, 2026. For Obstructive hypertrophic cardiomyopathy (label update based on MAPLE-HCM). sNDA; adds to an existing approval. Verified against the company announcement on 2026-10-16.
A PDUFA date is the FDA's target deadline to complete its review of a drug application — approval, a complete response letter (CRL), or an extension are all possible. What is a PDUFA date? This page is research information, not financial advice.
Source: sec.gov · Data checked October 20, 2026. How we check dates. Confirm dates against the company's or the FDA's announcement before acting.
Get an email when this FDA date moves or the decision lands
Track Cytokinetics, Incorporated (CYTK) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Questions about this FDA decision
- When is the PDUFA date for Aficamten (CK-3773274)?
- The FDA's PDUFA target action date for Aficamten (CK-3773274) is November 14, 2026. The FDA can act before that date, and the review can be extended.
- What is Aficamten (CK-3773274) being reviewed for?
- The application under FDA review covers Obstructive hypertrophic cardiomyopathy (label update based on MAPLE-HCM).
- Which company is developing Aficamten (CK-3773274)?
- Cytokinetics, Incorporated (CYTK).
- What can happen on a PDUFA date?
- The FDA approves the application, issues a complete response letter (CRL) listing what must be fixed before approval, or extends the review (typically by three months after a major amendment).